New York, June 6, 2026, 09:09 EDT
- Cooper Companies ended Friday at $67.34, up 8.6%. The company’s fiscal second-quarter earnings came in ahead of estimates.
- The move was notable as U.S. stocks fell, with S&P 500 losing 2.64% and Nasdaq down 4.18%.
- Investors are heading into a week that brings U.S. inflation data along with CooperVision trends in Asia-Pacific and the CooperSurgical review.
The Cooper Companies finished Friday at $67.34, gaining 8.6% for the session and up roughly 11.9% from Monday as U.S. markets headed into the weekend. The contact lens and women’s health name got a lift after beating on quarterly profit, with the stock getting new investor focus on earnings and portfolio prospects.
Cooper rose on Friday, even as stocks sold off. The Dow closed down 1.35%, the S&P 500 lost 2.64% and the Nasdaq Composite dropped 4.18%. A stronger May jobs report raised worry the Federal Reserve may stay hawkish and keep rates high or hike again.
Cooper’s stock hovered around $60 through most of the week before the company posted fiscal Q2 results late Thursday. Revenue was up 8% from last year at $1.082 billion. Non-GAAP diluted EPS, a profit metric that removes some items, climbed 26% to $1.21.
CooperCompanies CEO Al White said the company turned in a strong second quarter, with record revenue and non-GAAP EPS, according to the release. He added that Cooper has settled “substantially all” claims related to the CooperSurgical fertility media recall, a move investors have connected to Cooper’s ongoing strategic review. CooperCompanies
Legal costs weighed on results in the quarter. Cooper booked a GAAP diluted loss of 40 cents a share, mainly from a charge tied to the December 2023 voluntary recall at CooperSurgical. The company took a $271.6 million net pre-tax hit, which includes litigation liabilities. Some of that is expected to be covered by insurance.
Investors seemed to shrug off the charge for now. Barron’s said KeyBanc’s Brett Fishbin and William Korner pointed to the company’s strategic review and a possible CooperSurgical sale as the driver. J.P. Morgan’s Robbie Marcus kept his Neutral call but trimmed the price target to $71 from $80. The update on the review and the buyback plan “should be enough to put a floor on the share price,” Marcus wrote, according to Barron’s. Barron’s
CooperVision is still the main driver. Revenue for the contact lens unit climbed 8% to $723.5 million this quarter. Asia-Pacific sales were down 6% at $130.6 million, while the Americas and EMEA held steady. Reuters said White expects the Asia-Pacific region to be a drag on the segment.
White didn’t mince words on the earnings call. When asked about Asia-Pacific, he cited “Consumer weakness,” with Japan and China singled out, according to a transcript from Investing.com. Investing.com
Cooper cut its full-year revenue forecast to $4.285 billion to $4.321 billion but stuck to its fiscal 2026 non-GAAP EPS target of $4.58 to $4.66. Reuters quoted CFO Brian Andrews saying the guidance is “prudent,” pointing to higher costs and a weaker revenue view for CooperVision. CooperCompanies
Competitive read-across here looks limited. Reuters said Cooper and Bausch + Lomb may gain as buyers move to premium daily disposables and vision correction demand rises worldwide. But Cooper’s weakness in Asia-Pacific signals the trend isn’t everywhere.
Friday’s rally could be getting ahead of itself. Deeper slides in Asia-Pacific, tariff effects on margins, or a CooperSurgical review that doesn’t end with a sale or buyback-level cash could see investors turn back to the weaker revenue guide instead of the earnings beat. The litigation charge is another sign that there are still costs tied to the portfolio story.
Macro signals and company news are in focus for the week ahead. Investors get May CPI from the Bureau of Labor Statistics on Wednesday, June 10. May PPI follows on Thursday, June 11. Both inflation numbers arrive in the run-up to the Federal Reserve’s policy meeting set for June 16-17.
Cooper faces a clear question when the market opens: does that Friday gap hold? The earnings beat was enough to pull buyers back in. But the trimmed guidance, Asia-Pacific weakness, and the open CooperSurgical review all hang over the stock, giving traders pause.
